The World Health Organization recommends lenacapavir, a new HIV prevention drug, for high-risk groups and areas with high HIV rates.
This groundbreaking guidance was unveiled on July 14 at the 13th International AIDS Society conference in Kigali, amid growing concerns over funding for the global fight against HIV.
